U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 6, 2010
Nutra Pharma Corp.
(Exact name of registrant as specified in its charter)
| California | 000-32141 | 91-2021600 |
| (State or jurisdiction of | (Commission | (I.R.S. Employer |
| incorporation or organization) | File Number) | Identification No.) |
2776 University Drive
Coral Springs, Florida 33065
(Address of principal executive offices) (Zip Code)
Registrant's telephone number: 954 509-0911
Nutra Pharma Corp. is referred to herein as “we”, “our” or “us.
Item 2.02. Results of Operations and Financial Condition
On August 6, 2010, we issued a press release announcing our sales of $150,158 for our second fiscal quarter ended June 30, 2010.
A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit 99.1 Press Release
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
DATED: August 6, 2010
| Nutra Pharma Corp. | |||
| /s/ | Rik Deitsch | ||
| Rik Deitsch, President, Chief Executive Officer | |||